To find out more about current mental health studies you can view a list of studies on the NIHR Clinical Research Network Portfolio Database
The NIHR Clinical Research Network Cancer has been enormously successful in integrating clinical research into NHS clinical service provision, and both developing and delivering a large practice changing portfolio of clinical trials.
As the most integrated clinical research system in the world, the NIHR supports research studies through our funding programmes, training and supporting health researchers, and providing world-class research facilities. We also support dialogue between the life sciences industry and charities to benefit all, and facilitate the involvement of patients and the public to make research more effective.
Last year (2017/2018) the NIHR supported 228 studies on infectious disease and microbiology. The NIHR supported these studies through our funding programmes and our research schools and units. We also support infectious disease research through our research infrastructure and our training and career development awards for researchers.
Following the declaration of the swine flu as a pandemic, in preparations for the winter flu season in the autumn of 2009, the UK acquired two new influenza A H1N1 vaccines: Pandemrix and Celvapan. Due to the urgent need to provide effective vaccines in a short amount of time, both vaccines had been licensed for use without having undergone testing on children.
The University of Oxford’s Oxford Vaccine Group, which is linked to the NIHR Oxford Biomedical Research Centre, was appointed to conduct research to provide paediatric data on these vaccines, with fast-tracked ethical and regulatory approvals, due to the time critical nature of the research. After being awarded the research grant on 1 September 2009, the research team was able to redeploy resources - including the hiring of 80 staff - using NIHR infrastructure.
Combined, these rapid actions allowed the first vaccine administrations to take place within a month of commencing the study. The team reported an interim analysis of the data by mid-November, informing the Joint Committee for Immunisation and Vaccination and the Department of Health that both vaccines were well tolerated by participating children.
The aim of the Modify study was to test whether new monoclonal antibody drugs (drugs which were designed to neutralise the C. difficile toxins), developed by the pharmaceutical company Merck Sharp & Dohme Limited, would reduce the recurrence of the infection when used alongside standard antibiotic treatment.
Seasonal flu vaccines are essential to the prevention of flu worldwide. Over the last two years the NIHR Clinical Research Network has successfully supported studies in the UK for Seqirus – one of the world’s leading flu vaccine providers. Insight Monthly asked Dr David Bibby, Clinical Operations and vaccine specialist at Seqirus, why their relationship with the Network has been so successful.
Insight magazine speaks to researchers in the capital about how a new approach to diagnosing TB could translate into significant savings for the NHS and a major improvement in patient experience.
Men find self-testing acceptable to test for sexually transmitted infections
You can find out more about infectious disease and microbiology studies in your area through the UK Clinical Trials Gateway.